Michelle Rex Murphy, MS, OTR/L, CEAS, REAS, ergonomics specialist for Mass General Brigham, shares these quick stretches to do throughout the day.
- Nonanxious patients responded significantly better to the lowest ketamine dose that was tested than participants with anxiety did
- Forty minutes after the start of ketamine infusion, people with anxious depression experienced a lower level of dissociative symptoms as compared to subjects without anxious depression
- Mass General researchers have found ketamine to be an effective choice for some patients with treatment-resistant depression
About half of patients with major depression also suffer with anxiety, making their disorder particularly difficult to treat.
The anesthetic ketamine has become popular over the past decade as a remedy for depressed patients who have become resistant to standard treatments, but its effectiveness in treating anxious depression was unclear.
Researchers at Massachusetts General Hospital set out to determine the effectiveness of intravenous ketamine at four different doses in treatment-resistant depression, including anxious depression. They compared the drug to the sedative midazolam, and when all four treatment groups were combined, they found that ketamine was an equally effective choice.
Methodology of the Study
The study, which enrolled 99 patients, was led by Mass General research fellow Naji Salloum, MD, and George Papakostas, MD, director of Treatment-Resistant Depression Studies in the Depression Clinical and Research Program. The study was sponsored by the National Institute of Mental Health's Rapidly Acting Treatments for Treatment-Resistant Depression (RAPID), which is a research program that promotes the development of fast-acting therapies for treatment-resistant depression.
The patients in the trial ranged in age from 18 to 70, and 45 of them were defined as having anxious depression as measured by the Hamilton Depression Rating Scale (HAMD), which is widely used to assess the severity of symptoms. Participants either received ketamine at one of the four doses, or midazolam at a dose of 0.045 mg/kg.
From Party Drug to Antidepressant
Ketamine, which has built a reputation as the "party" drug for its popularity among nightclub aficionados, is fast-acting, often producing mood changes within hours, as compared to days for most popular antidepressants. Mass General researchers set out to determine how the patients in the trial were feeling during the first three days after their infusion.
Excerpt from study
Taken together, our results, as well as results of the two previous reports, highlight the potential role of ketamine in the treatment of anxious depression.
Dr. Salloum and colleagues found that this drug is equally effective in treatment-resistant depression with or without anxiety, when measured at both day one and day three after infusion. However, on day three, the nonanxious patients did respond significantly better to the lowest dose tested (0.1 mg/kg) than the anxious group did.
Interestingly, within 40 minutes of receiving the infusion, patients with anxiety experienced fewer "dissociative" symptoms, such as memory loss and a sense of detachment, than participants without anxious depression did. The study authors suggested one reason for that may be that people suffering from anxiety are often treated with the sedative benzodiazepine, which can blunt dissociative symptoms.
There were some other limitations to this study. For instance, the authors tracked changes in a subset of the HAMD measurement scale rather than focusing on the full HAMD-17 score. They did not take HAMD-17 measurements after the baseline testing, and that "prevented us from assessing whether anxiety symptoms improved as rapidly and thoroughly as core depressive symptoms did," they wrote.
Hope for Treatment-Resistant Patients
The Mass General researchers believe their findings are important because there are so few good options for helping patients with depression who have grown resistant to standard treatments. Patients with anxious depression "do not maintain response or remission, and may have a higher side-effect burden compared to subjects with nonanxious depression," the authors wrote.
This new evidence adds weight to two previous studies that explored how the drug affected anxiety levels, the authors noted. One of these trials, which compared the drug to a placebo in treatment-resistant patients, showed ketamine lowered symptoms of depression and lengthened the time to relapse. The second demonstrated significant benefits for the drug over midazolam in anxious and nonanxious depression.
"Taken together, our results, as well as results of the two previous reports, highlight the potential role of ketamine in the treatment of anxious depression," they concluded.
Contributors: George Papakostas, MD and Naji Salloum, MD.
- May | 18 | 2021
After more than a year of working from home, many people face the prospect of going back to the office. Soo Jeong Youn, PhD, talks through a few strategies to help make the transition back to the office a bit easier.
- May | 7 | 2021
Music and Mass General. These are the two things Andrew Marshall credits with saving his life, leading him to live out his passion for music today as a contestant on “The Voice.”
- Feb | 12 | 2021
After a successful launch on the pediatric inpatient units, the Journals of Hope Program has expanded into the Pediatric Intensive Care Unit, where patients and families can find strength and hope through the power of writing.
- Jan | 22 | 2021
Dismorfia de Zoom: Cómo las llamadas frecuentes por Zoom podrían estar cambiando la forma en que nos percibimos a nosotros mismos
Al principio parecía inofensivo, pero a medida que la pandemia continúa, no puedo evitar darme cuenta de cómo las llamadas de Zoom podrían estar desencadenando nuevas inseguridades. ¿Siempre hemos tenido este aspecto? ¿Estamos utilizando filtros para mejorar nuestra apariencia?
- Patient Education
- Jan | 21 | 2021
With recommendations to stay at home this winter to help stop the spread of COVID-19, David Mischoulon, MD, PhD, offers insights on SAD and how to stay well at home this winter.